A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
PHASE2
The primary objective of this trial is to estimate and compare the 12-week ...
Status
Completed
Location
1239.3.4402 Boehringer Ingelheim Investigational Site